Research ArticleEvolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Robert R. Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C. Griffen
DOI: 10.2337/dc13-2955 Published 1 March 2015
Robert R. Henry
1Center for Metabolic Research, VA San Diego Healthcare System, San Diego, CA
2University of California, San Diego, La Jolla, CA
Julio Rosenstock
3Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX
Steven Edelman
1Center for Metabolic Research, VA San Diego Healthcare System, San Diego, CA
2University of California, San Diego, La Jolla, CA
Sunder Mudaliar
1Center for Metabolic Research, VA San Diego Healthcare System, San Diego, CA
2University of California, San Diego, La Jolla, CA
Alexandros-Georgios Chalamandaris
4Bristol-Myers Squibb, Braine-l'Alleud, Belgium
Sreeneeranj Kasichayanula
5Bristol-Myers Squibb, Princeton, NJ
Allyson Bogle
5Bristol-Myers Squibb, Princeton, NJ
Nayyar Iqbal
5Bristol-Myers Squibb, Princeton, NJ
James List
5Bristol-Myers Squibb, Princeton, NJ
Steven C. Griffen
5Bristol-Myers Squibb, Princeton, NJ
Supplementary Data
Files in this Data Supplement: